\n
<\/p>\n
Andrew Arno, a director at Oncocyte Corp (NASDAQ:OCX), recently acquired 12,500 shares of the company\u2019s common stock at a weighted average price of $2.108 per share. This transaction, valued at approximately $26,350, took place on December 26, 2024. Following this purchase, Arno directly owns 81,554 shares. Additionally, Arno holds indirect ownership through JBA Investments LLC and MJA Investments LLC, where he serves as the manager with the right to vote and dispose of securities. InvestingPro<\/a> analysis reveals the company’s current market cap stands at $35.52 million, with several additional insights available through the comprehensive Pro Research Report, which provides deep-dive analysis of over 1,400 US stocks.<\/p>\n In other recent news, Oncocyte Corp. has been making strides in the diagnostics field, with research indicating its DetermaCNI\u2122 assay could be a non-invasive method for diagnosing central nervous system tumors. This development could impact the roughly 300,000 U.S. patients annually diagnosed with primary brain tumors or metastasis, representing a potential $300 million market opportunity. The company’s recent studies show promising results, with SCNAs found in the fluid of 10 out of 12 patients with confirmed central nervous system cancers.<\/p>\n In addition to its advancements in tumor diagnosis, Oncocyte has seen success in the transplant diagnostics market with the launch of its GraftAssure RUO product. The company is preparing for the release of its upcoming VitaGraft Kidney kitted test, anticipated to launch in the fourth quarter of 2025, pending FDA approval. Oncocyte’s strategy involves securing agreements with at least 20 transplant centers across the United States and Germany by the end of 2025.<\/p>\n Furthermore, Oncocyte has raised $10.2 million to support its expansion of transplant testing services and the development of its oncology product, DetermaIO. The company projects an annual revenue of $1 million per site by the end of 2025. Needham analysts have maintained their Buy rating for Oncocyte, following the positive developments with the GraftAssure RUO product. These recent developments highlight Oncocyte’s commitment to innovation and growth in the diagnostics field.<\/p>\n This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n<\/div>\n